Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Data Act Must Consider ‘Sectoral Peculiarities’ Says Medtech Industry

Executive Summary

The European Commission’s proposed Data Act is among a growing pile of horizontal regulations set to impact the medtech industry. But changes should be made to protect trade secrets and other sector-specific nuances, MedTech Europe warns.

You may also be interested in...



EU Opening Pandora’s Box With Data Act, Warns Medical Imaging Body COCIR

Medtech trade body COCIR has joined forces with representatives from industries within and outside health care to warn that the European Commission’s proposed EU Data Act is a “huge leap into the unknown.”

EU Digital Tech Trade Body Weighs In On Medical Device ‘Over-Regulation’ Risk

While the European Health Data Space and its objectives should be a positive regulatory development for the EU health sector, DIGITALEUROPE stresses that the risk of counterproductive conflicts with other proposed laws around AI and data must be addressed.

Beyond MDR: How Stricter EU Rules On AI And Data Are Set To Impact Medtech

The second half of 2022 has seen much debate and concern from EU medtech stakeholders around numerous proposed horizontal rules that will affect digital products. Changes in policies around AI, cybersecurity and data-sharing are likely to be an even bigger theme in 2023.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel